A real-world comparative analysis of carfilzomib and other systemic multiple myeloma chemotherapies in a US community oncology setting

BACKGROUND: Most multiple myeloma (MM) patients ultimately progress, with remission duration decreasing after first relapse. Recently, novel agents have been approved for the treatment of relapsed MM. There is a paucity of real-world data on these treatments. We sought to compare time to next treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: Rifkin, Robert M., Medhekar, Rohan, Amirian, E. Susan, Aguilar, Kathleen M., Wilson, Thomas, Boyd, Marley, Mezzi, Khalid, Panjabi, Sumeet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348507/
https://www.ncbi.nlm.nih.gov/pubmed/30719266
http://dx.doi.org/10.1177/2040620718816699

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348507/
https://www.ncbi.nlm.nih.gov/pubmed/30719266
http://dx.doi.org/10.1177/2040620718816699

Ejemplares similares